Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 10:13:934343.
doi: 10.3389/fimmu.2022.934343. eCollection 2022.

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

Affiliations
Review

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

Tobias Riet et al. Front Immunol. .

Abstract

CAR (Chimeric Antigen Receptor) T-cell therapy has revolutionized the field of oncology in recent years. This innovative shift in cancer treatment also provides the opportunity to improve therapies for many patients suffering from various autoimmune diseases. Recent studies have confirmed the therapeutic suppressive potential of regulatory T cells (Tregs) to modulate immune response in autoimmune diseases. However, the polyclonal character of regulatory T cells and their unknown TCR specificity impaired their therapeutic potency in clinical implementation. Genetical engineering of these immune modulating cells to express antigen-specific receptors and using them therapeutically is a logical step on the way to overcome present limitations of the Treg strategy for the treatment of autoimmune diseases. Encouraging preclinical studies successfully demonstrated immune modulating properties of CAR Tregs in various mouse models. Still, there are many concerns about targeted Treg therapies relating to CAR target selectivity, suppressive functions, phenotype stability and safety aspects. Here, we summarize recent developments in CAR design, Treg biology and future strategies and perspectives in CAR Treg immunotherapy aiming at clinical translation.

Keywords: adoptive therapy; autoimmune diseases; chimeric antigen receptor (CAR); immunosuppressive therapy; regulatory (Treg) cell.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The evolution of CARs.

Similar articles

Cited by

References

    1. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. . A special population of regulatory T cells potentiates muscle repair. Cell (2013) 155(6):1282–95. doi: 10.1016/j.cell.2013.10.054 - DOI - PMC - PubMed
    1. Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, et al. . A distinct function of regulatory t cells in tissue protection. Cell (2015) 162(5):1078–89. doi: 10.1016/j.cell.2015.08.021 - DOI - PMC - PubMed
    1. Kempkes RWM, Joosten I, Koenen H, He X. Metabolic pathways involved in regulatory t cell functionality. Front Immunol (2019) 10:2839. doi: 10.3389/fimmu.2019.02839 - DOI - PMC - PubMed
    1. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology (2006) 117(3):289–300. doi: 10.1111/j.1365-2567.2005.02317.x - DOI - PMC - PubMed
    1. Kos K, Aslam MA, Wellenstein MD, Pieters W, van Weverwijk A, Duits DEM, et al. . Tumor-educated tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche. Cell Rep (2022) 38(9):110447. doi: 10.1016/j.celrep.2022.110447 - DOI - PubMed

Publication types

Substances